表紙
市場調查報告書

阿茲海默症:市場預測與分析

Alzheimer's Disease Market and Forecast Analysis 2034

出版商 Datamonitor Healthcare 商品編碼 365211
出版日期 內容資訊 英文 300 Pages
商品交期: 最快1-2個工作天內
價格
阿茲海默症:市場預測與分析 Alzheimer's Disease Market and Forecast Analysis 2034
出版日期: 2019年02月25日內容資訊: 英文 300 Pages
簡介

阿茲海默症,是慢慢影響記憶、認識、功能,不可逆性的進行性、神經退化、致命的疾病。阿茲海默症,是老年人的失智症的最常見的原因。

本報告提供阿茲海默症的治療藥市場相關調查分析,市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:阿茲海默症

  • 概要
  • 摘要整理
  • 市場概要、趨勢
  • 市場定義、手法
  • ADUCANUMAB
  • ARICEPT (DONEPEZIL)
  • CRENEZUMAB
  • EXELON/EXELON PATCH (RIVASTIGMINE)
  • NAMENDA/XR (MEMANTINE)
  • RAZADYNE (GALANTAMINE)
  • RVT-101
  • 一次調查手法

治療:阿茲海默症

  • 概要
  • 摘要整理
  • 一次調查手法
  • 疾病定義、診斷
  • 患者區分
  • 國家治療樹
  • 目前治療選擇
  • 處方趨勢
  • 阿茲海默症的未滿足需求

流行病學:阿茲海默症

  • 摘要整理
  • 疾病的背景
  • 手法
  • 預測
  • 參考文獻
  • 附錄:輕度認知障礙 (MCI)

上市藥:阿茲海默症

  • 摘要整理
  • 產品概要
  • 產品簡介:ARICEPT
  • 產品簡介:EXELON/EXELON PATCH
  • 產品簡介:NAMENDA
  • 產品簡介:RAZADYNE

開發平台:阿茲海默症

  • 摘要整理
  • 臨床實驗平台概要
  • 臨床試驗的設計
  • 最近中止的藥物
  • 其他製藥情報開發平台資源
  • 產品簡介 (後期) :LMTX
  • 產品簡介 (後期) :RVT-101
  • 產品簡介 (後期) :ADUCANUMAB
  • 產品簡介 (後期) :AZELIRAGON
  • 產品簡介 (後期) :CRENEZUMAB
  • 產品簡介 (後期) :GANTENERUMAB
  • 產品簡介 (後期) :VERUBECESTAT
目錄
Product Code: DMKC4740

Overview:

Alzheimer's disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affects memory, cognition, and function. Alzheimer's disease is the most common cause of dementia among older people. Dementia is the loss of cognitive functioning - thinking, remembering, and reasoning - and behavioral abilities, to such an extent that it interferes with a person's daily life and activities. Dementia ranges in severity from mild to the most severe stage, when the person must depend completely on others for basic activities of daily living.

Market Snapshot:

  • Solanezumab's failure will likely impede the uptake of future beta amyloid antibodies.
  • Datamonitor Healthcare's survey sheds light on the changing landscape of prescribing patterns in Alzheimer's disease.
  • Alzheimer's disease inflicts a significant burden in the US, Japan, and five major EU markets.
  • A number of commercially successful brands are now reaching the end of their lifecycle.
  • Solanezumab's suspension has not stifled ongoing development of other amyloid-targeting therapies.

TABLE OF CONTENTS

FORECAST: ALZHEIMER'S DISEASE (Published on 21 June 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • MARKET OVERVIEW AND TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • ADUCANUMAB
  • ARICEPT (DONEPEZIL)
  • CRENEZUMAB
  • EXELON/EXELON PATCH (RIVASTIGMINE)
  • NAMENDA/XR (MEMANTINE)
  • RAZADYNE (GALANTAMINE)
  • RVT-101
  • PRIMARY RESEARCH METHODOLOGY

TREATMENT: ALZHEIMER'S DISEASE (Published on 21 June 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • COUNTRY TREATMENT TREES
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • UNMET NEEDS IN ALZHEIMER'S DISEASE

EPIDEMIOLOGY: ALZHEIMER'S DISEASE (Published on 25 February 2019)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX: MILD COGNITIVE IMPAIRMENT

MARKETED DRUGS: ALZHEIMER'S DISEASE (Published on 21 June 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ARICEPT
  • PRODUCT PROFILE: EXELON/EXELON PATCH
  • PRODUCT PROFILE: NAMENDA
  • PRODUCT PROFILE: RAZADYNE

PIPELINE: ALZHEIMER'S DISEASE (Published on 21 June 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • CLINICAL TRIAL DESIGN
  • RECENTLY DISCONTINUED DRUGS
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): LMTX
  • PRODUCT PROFILE (LATE STAGE): RVT-101
  • PRODUCT PROFILE (LATE STAGE): ADUCANUMAB
  • PRODUCT PROFILE (LATE STAGE): AZELIRAGON
  • PRODUCT PROFILE (LATE STAGE): CRENEZUMAB
  • PRODUCT PROFILE (LATE STAGE): GANTENERUMAB
  • PRODUCT PROFILE (LATE STAGE): VERUBECESTAT

LIST OF FIGURES

  • Figure 1: Alzheimer's disease market sales value in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 2: Alzheimer's disease drug class sales in the US, Japan, and five major EU markets, 2015-24
  • Figure 3: Sales of cholinesterase inhibitors in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 4: Sales of NMDA receptor antagonists in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 5: Alzheimer's disease market sales value by disease severity in the US, Japan, and five major EU markets, 2015-24
  • Figure 6: Patient-based forecast methodology for Alzheimer's disease
  • Figure 7: Price sources and calculations, by country
  • Figure 8: Aducanumab sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 9: Aricept sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 10: Crenezumab sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 11: Exelon/Exelon Patch sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 12: Namenda/XR sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 13: Razadyne sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 14: RVT-101 sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 15: Hypothetical model of dynamic biomarkers taking place with disease severity
  • Figure 16: Neurologist-reported Alzheimer's disease diagnosis rates, by country, 2015
  • Figure 17: Hypothesized beta-amyloid pathway in Alzheimer's disease and therapeutic strategies
  • Figure 18: Hypothesized tau pathway in Alzheimer's disease and therapeutic strategies
  • Figure 19: The dynamics in biomarkers of the Alzheimer's disease pathological cascade
  • Figure 20: Estimated prevalent and diagnosed prodromal and Alzheimer's disease patient populations in the US, Japan, and five major EU markets, by country, 2015
  • Figure 21: Diagnosed Alzheimer's disease patients in the US, Japan, and five major EU markets, by disease severity and country, 2015
  • Figure 22: Estimated prevalent, diagnosed, and drug-treated prodromal and Alzheimer's disease patients in the US, Japan, and five major EU markets, by country, 2015
  • Figure 23: Proportion of drug-treated patients in the US, Japan, and five major EU markets, by disease severity and country (%), 2015
  • Figure 24: Pharmacological treatment rates for diagnosed Alzheimer's patients in the US, Japan, and five major EU markets, by disease severity and country (%), 2015
  • Figure 25: Treatment choices for patients diagnosed with prodromal Alzheimer's disease in the US, Japan, and five major EU markets, by country (%), 2015
  • Figure 26: Treatment choices for patients diagnosed with mild Alzheimer's disease in the US, Japan, and five major EU markets, by country (%), 2015
  • Figure 27: Treatment choices for patients diagnosed with moderate Alzheimer's disease in the US, Japan, and five major EU markets, by country (%), 2015
  • Figure 28: Treatment choices for patients diagnosed with severe Alzheimer's disease in the US, Japan, and five major EU markets, by country (%), 2015
  • Figure 29: Prescription trends in patients diagnosed with prodromal Alzheimer's disease in the US, Japan, and five major EU markets, by country (%), 2015
  • Figure 30: Prescription trends in patients diagnosed with mild Alzheimer's disease in the US, Japan, and five major EU markets, by country (%), 2015
  • Figure 31: Prescription trends in patients diagnosed with moderate Alzheimer's disease in the US, Japan, and five major EU markets, by country (%), 2015
  • Figure 32: Prescription trends in patients diagnosed with severe Alzheimer's disease in the US, Japan, and five major EU markets, by country (%), 2015
  • Figure 33: Preference for rivastigmine patch over oral formulation for all severities of Alzheimer's disease, by country (%), 2015
  • Figure 34: Proportion of Alzheimer's disease patients receiving either memantine monotherapy or in combination, by country (%), 2015
  • Figure 35: Compliance rates to oral versus transdermal patch formulations in patients with Alzheimer's disease, by country (%), 2015
  • Figure 36: Key unmet needs for Alzheimer's disease, 2015
  • Figure 37: Impact of symptomatic versus disease-modifying drugs on quality of life/life expectancy over the course of the disease
  • Figure 38: NHS's recommended referral pathway for patients presenting to primary care with dementia
  • Figure 39: Trends in total prevalent cases of Alzheimer's disease in the US, Japan, and five major EU markets, by country, 2018-38
  • Figure 40: Aricept for Alzheimer's disease - SWOT analysis
  • Figure 41: Datamonitor Healthcare's drug assessment summary of Aricept in Alzheimer's disease
  • Figure 42: Datamonitor Healthcare's drug assessment summary of Aricept in Alzheimer's disease
  • Figure 43: Exelon/Exelon Patch for Alzheimer's disease - SWOT analysis
  • Figure 44: Datamonitor Healthcare's drug assessment summary of Exelon in Alzheimer's disease
  • Figure 45: Datamonitor Healthcare's drug assessment summary of Exelon in Alzheimer's disease
  • Figure 46: Namenda for Alzheimer's disease - SWOT analysis
  • Figure 47: Datamonitor Healthcare's drug assessment summary of Namenda in Alzheimer's disease
  • Figure 48: Datamonitor Healthcare's drug assessment summary of Namenda in Alzheimer's disease
  • Figure 49: Razadyne for Alzheimer's disease - SWOT analysis
  • Figure 50: Datamonitor Healthcare's drug assessment summary of Razadyne in Alzheimer's disease
  • Figure 51: Datamonitor Healthcare's drug assessment summary of Razadyne in Alzheimer's disease
  • Figure 52: Clinical trial designs proposed to determine disease modification
  • Figure 53: LMTX for Alzheimer's disease - SWOT analysis
  • Figure 54: Datamonitor Healthcare's drug assessment summary of LMTX in Alzheimer's disease
  • Figure 55: Datamonitor Healthcare's drug assessment summary of LMTX in Alzheimer's disease
  • Figure 56: RVT-101 for Alzheimer's disease - SWOT analysis
  • Figure 57: Datamonitor Healthcare's drug assessment summary of RVT-101 in Alzheimer's disease
  • Figure 58: Datamonitor Healthcare's drug assessment summary of RVT-101 in Alzheimer's disease
  • Figure 59: Aducanumab for Alzheimer's disease - SWOT analysis
  • Figure 60: Datamonitor Healthcare's drug assessment summary of aducanumab in Alzheimer's disease
  • Figure 61: Datamonitor Healthcare's drug assessment summary of aducanumab in Alzheimer's disease
  • Figure 62: Azeliragon for Alzheimer's disease - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of azeliragon in Alzheimer's disease
  • Figure 64: Datamonitor Healthcare's drug assessment summary of azeliragon in Alzheimer's disease
  • Figure 65: Crenezumab for Alzheimer's disease - SWOT analysis
  • Figure 66: Datamonitor Healthcare's drug assessment summary of crenezumab in Alzheimer's disease
  • Figure 67: Datamonitor Healthcare's drug assessment summary of crenezumab in Alzheimer's disease
  • Figure 68: Gantenerumab for Alzheimer's disease - SWOT analysis
  • Figure 69: Datamonitor Healthcare's drug assessment summary of gantenerumab in Alzheimer's disease
  • Figure 70: Datamonitor Healthcare's drug assessment summary of gantenerumab in Alzheimer's disease
  • Figure 71: Verubecestat for Alzheimer's disease - SWOT analysis
  • Figure 72: Datamonitor Healthcare's drug assessment summary of verubecestat in Alzheimer's disease
  • Figure 73: Datamonitor Healthcare's drug assessment summary of verubecestat in Alzheimer's disease
  • Figure 74: Hypothetical model of dynamic biomarkers taking place with disease severity

LIST OF TABLES

  • Table 1: Alzheimer's disease market sales value in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 2: Alzheimer's disease drug class sales in the US, Japan, and five major EU markets ($m), 2015-24
  • Table 3: Sales of cholinesterase inhibitors in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 4: Sales of NMDA receptor antagonists in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 5: Alzheimer's disease market sales value by disease severity in the US, Japan, and five major EU markets ($m), 2015-24
  • Table 6: Summary of drug classes and molecules in Datamonitor Healthcare's Alzheimer's disease patient-based forecast
  • Table 7: Exchange rates used for calculating prices
  • Table 8: Estimated patent expiry/loss of exclusivity dates for key marketed brands in Alzheimer's disease in the US, Japan, and five major EU markets, by country
  • Table 9: Estimated launch dates of key late-stage pipeline products in Alzheimer's disease, by country, 2015-24
  • Table 10: Aducanumab's dose and price assumptions, by country, 2016
  • Table 11: Aducanumab sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 12: Aricept sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 13: Crenezumab's dose and price assumptions, by country, 2016
  • Table 14: Crenezumab sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 15: Exelon/Exelon Patch sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 16: Namenda/XR sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 17: Razadyne sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 18: RVT-101 sales for Alzheimer's disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 19: Neurologists surveyed for the Alzheimer's disease primary research study, 2015
  • Table 20: Pipeline products discussed in the key opinion leader research interviews
  • Table 21: Neurologists surveyed for the Alzheimer's disease primary research study, 2015
  • Table 22: Common clinical features of Alzheimer's disease
  • Table 23: Dementia caregiver tasks
  • Table 24: Estimated number of diagnosed Alzheimer's disease patients in the US, Japan, and five major EU markets, by disease severity and country, 2015
  • Table 25: Estimated number of drug-treated Alzheimer's disease patients in the US, Japan, and five major EU markets, by disease severity and country, 2015
  • Table 26: Leading therapies for Alzheimer's disease
  • Table 27: Commonly used guidelines for the treatment of Alzheimer's disease
  • Table 28: Pharmacological treatment rates for diagnosed Alzheimer's patients in the US, Japan, and five major EU markets, by disease severity and country (%), 2015
  • Table 29: Prescription trends in patients diagnosed with prodromal Alzheimer's disease in the US, Japan, and five major EU markets, by country (%), 2015
  • Table 30: Prescription trends in patients diagnosed with mild Alzheimer's disease in the US, Japan, and five major EU markets, by country (%), 2015
  • Table 31: Prescription trends in patients diagnosed with moderate Alzheimer's disease in the US, Japan, and five major EU markets, by country (%), 2015
  • Table 32: Prescription trends in patients diagnosed with severe Alzheimer's disease in the US, Japan, and five major EU markets, by country (%), 2015
  • Table 33: Summary of the global and cognitive response of Alzheimer's disease patients to acetylcholinesterase inhibitor treatment
  • Table 34: Aricept's side-effect profile
  • Table 35: Sources used for the epidemiological analysis of Alzheimer's disease in the US, Japan, and EU markets, by country
  • Table 36: Total prevalent cases of Alzheimer's disease in the US, Japan, and five major EU markets, by country, 2018-38
  • Table 37: Total prevalent cases of mild cognitive impairment due to Alzheimer's disease in the US, Japan, and five major EU markets, by country, 2018-38
  • Table 38: Key marketed drugs for Alzheimer's disease
  • Table 39: Aricept drug profile
  • Table 40: Aricept pivotal trial data in Alzheimer's disease
  • Table 41: Exelon/Exelon Patch drug profile
  • Table 42: Exelon pivotal trial data in Alzheimer's disease
  • Table 43: Exelon Patch pivotal trial data in Alzheimer's disease
  • Table 44: Namenda drug profile
  • Table 45: Namenda pivotal trial data in Alzheimer's disease
  • Table 46: Razadyne drug profile
  • Table 47: Razadyne pivotal trial data in Alzheimer's disease
  • Table 48: Phase III pipeline products in development for Alzheimer's disease
  • Table 49: FDA and EMA recommendations for clinical trial endpoints in Alzheimer's disease
  • Table 50: FDA and EMA recommendations on clinical trial design to demonstrate disease-modifying effects
  • Table 51: Encenicline drug profile
  • Table 52: Encenicline late-phase trials in Alzheimer's disease
  • Table 53: Idalopirdine drug profile
  • Table 54: Idalopirdine late-phase trials in Alzheimer's disease
  • Table 55: Solanezumab drug profile
  • Table 56: Solanezumab late-phase trials in Alzheimer's disease
  • Table 57: LMTX drug profile
  • Table 58: LMTX Phase III data in Alzheimer's disease
  • Table 59: LMTX Phase III trials in Alzheimer's disease
  • Table 60: RVT-101 drug profile
  • Table 61: RVT-101 Phase II data in Alzheimer's disease
  • Table 62: RVT-101 Phase III trials in Alzheimer's disease
  • Table 63: Aducanumab drug profile
  • Table 64: Aducanumab Phase Ib data in Alzheimer's disease
  • Table 65: Aducanumab Phase III trials in Alzheimer's disease
  • Table 66: Azeliragon drug profile
  • Table 67: Azeliragon Phase Iib data in Alzheimer's disease
  • Table 68: Azeliragon Phase III trials in Alzheimer's disease
  • Table 69: Crenezumab drug profile
  • Table 70: Crenezumab Phase II data in Alzheimer's disease
  • Table 71: Crenezumab Phase III trials in Alzheimer's disease
  • Table 72: Gantenerumab drug profile
  • Table 73: Gantenerumab Phase III data in Alzheimer's disease
  • Table 74: Gantenerumab Phase III trials in Alzheimer's disease
  • Table 75: Verubecestat drug profile
  • Table 76: Verubecestat Phase Ib data in Alzheimer's disease
  • Table 77: Verubecestat Phase II/III trials in Alzheimer's disease